Target type: molecularfunction
Catalysis of the reaction: S-adenosyl-L-methionine + histone H3 L-lysine (position 4) = S-adenosyl-L-homocysteine + histone H3 N6-methyl-L-lysine (position 4). This reaction is the addition of up to three methyl groups to the lysine residue at position 4 of the histone H3 protein. [PMID:12086618]
Histone H3K4 methyltransferase activity is a crucial epigenetic modification that plays a vital role in regulating gene expression. It involves the transfer of a methyl group from a donor molecule, typically S-adenosyl methionine (SAM), to the lysine 4 (K4) residue on the N-terminal tail of histone H3. This methylation event can occur at different levels, resulting in mono-, di-, or tri-methylation (H3K4me1, H3K4me2, H3K4me3). Each methylation state has distinct regulatory functions.
H3K4 methylation is primarily associated with active gene transcription. H3K4me3, the most highly methylated state, is typically found at promoters of actively transcribed genes. It recruits various chromatin remodeling complexes and transcription factors that facilitate gene activation. H3K4me2 is often found in enhancers, regulatory elements that enhance gene expression, and can also be present at promoters, contributing to the overall transcriptional activity. H3K4me1 is generally associated with poised or primed genes, indicating a potential for future transcription.
Histone H3K4 methyltransferases, also known as SET domain-containing proteins, are a family of enzymes responsible for catalyzing this methylation reaction. Some key members of this family include:
- **SET1/COMPASS complex:** This multi-protein complex is responsible for H3K4me1, H3K4me2, and H3K4me3 deposition. It is essential for developmental processes and cell fate decisions.
- **MLL complex:** This complex is involved in H3K4me3 deposition at specific genes, particularly those involved in hematopoiesis. Mutations in MLL are associated with leukemia.
- **ASH1L complex:** This complex contributes to H3K4me2 and H3K4me3 deposition, playing a role in neuronal development and differentiation.
In addition to its role in gene activation, H3K4 methylation is also implicated in various other cellular processes, including DNA replication, DNA repair, and cell cycle regulation. Dysregulation of H3K4 methylation can lead to developmental defects, cancer, and other diseases.
The precise molecular function of H3K4 methyltransferase activity is complex and involves intricate interactions between various proteins and DNA elements. This intricate interplay ultimately shapes the epigenetic landscape and plays a crucial role in regulating gene expression and cellular function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Histone-lysine N-methyltransferase 2A | A histone-lysine N-methyltransferase 2A that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q03164] | Homo sapiens (human) |
Histone-lysine N-methyltransferase 2D | A histone-lysine N-methyltransferase 2D that is encoded in the genome of human. [PRO:DNx, UniProtKB:O14686] | Homo sapiens (human) |
Histone-lysine N-methyltransferase 2B | A histone-lysine N-methyltransferase 2B that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Histone-lysine N-methyltransferase 2C | A histone-lysine N-methyltransferase 2C that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NEZ4] | Homo sapiens (human) |
Histone-lysine N-methyltransferase SETMAR | A histone-lysine N-methyltransferase SETMAR that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q53H47] | Homo sapiens (human) |
Histone-lysine N-methyltransferase 2A | A histone-lysine N-methyltransferase 2A that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q03164] | Homo sapiens (human) |
WD repeat-containing protein 5 | A WD repeat-containing protein 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P61964] | Homo sapiens (human) |
Histone-lysine N-methyltransferase 2D | A histone-lysine N-methyltransferase 2D that is encoded in the genome of human. [PRO:DNx, UniProtKB:O14686] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
lansoprazole | Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
omeprazole | 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole. Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
rabeprazole | Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
scutellarein | scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7. scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein | tetrahydroxyflavone | metabolite |
dexlansoprazole | Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE. | benzimidazoles; sulfoxide | |
4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine | N-arylpiperazine; thienopyrimidine | ||
gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source | ||
oicr-9429 | OICR-9429: antineoplastic; structure in first source |